Memdes Bioworks Limited’s original MEMDDS™ complex drug research and development platform uses a combination of new materials and pharmaceutical engineering to prepare sustained-release microspheres, abandoning the traditional homogeneous preparation of sustained-release microspheres. Select appropriate new materials according to the drug system to prepare sustained-release microspheres, and precisely control the drug release time of sustained-release microspheres.
At the same time, Memdes Bioworks Limited is a medical and engineering research and development team composed of pharmaceuticals, pharmacology, new materials, chemicals, medical equipment and other interdisciplinary disciplines, forming equipment and processes with fully independent intellectual property rights, and getting rid of the technology monopoly of foreign companies. Get rid of the monopoly of foreign technology, drug system, preparation equipment, and materials to achieve domestic research and development with independent intellectual property rights. Memdes’s slow-release microspheres have entered the kilogram-level pilot test stage.

The platform is chaired by Associate Professor Wenwei Zhong, a graduate of the University of New South Wales, Australia. The core members include a number of young researchers with chemical engineering and pharmacy backgrounds from renowned universities at home and abroad. The platform utilises self-developed membrane dispersion materials and devices for the preparation of slow-release microspheres, and is actively developing relevant intellectual property rights, with patents and industry standards already in place.